Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Renewed optimism for the treatment of Alzheimer’s disease
Scientists from the Flanders Interuniversity Institute for Biotechnology (VIB) have demonstrated that leakage appears to occur between the blood vessels and the brain, as a result of which
Scientists from the Flanders Interuniversity Institute for Biotechnology (VIB) have demonstrated that leakage appears to occur between the blood vessels and the brain, as a result of which
Researchers at the McGill University Health Centre (MUHC) in Canada have investigated a debilitating hereditary form of migraine which is accompanied by visual impairments known as auras. The
454 Life Sciences and Roche entered into the five-year, world-wide agreement in May, 2005. Under the terms of the agreement, 454 Life Sciences will receive up to $62
Under the agreement Genentech will use the Immunogen compounds in combination with its own therapeutic antibodies, on particular undisclosed targets. Shares in ImmunoGen climbed almost 10% in the
Entry inhibitors like aplaviroc represent a new mechanism of action in this class of drugs, and potentially a new way of treating patients with HIV. They work by
C difficile infection, which is characterized by diarrhea and colitis, represents one of the most common hospital acquired infections around the world. A new virulent strain of C
Tapestry expects savings from this downsizing, and other cost saving measures, to total approximately $7.4 million through the end of 2006; however about 14 people, or 30% of
Namenda was approved by the FDA for the treatment of moderate to severe Alzheimer’s disease in October 2003. However, the US regulator has now raised questions regarding the
Pierre Fabre has licensed the US and Canadian rights for oral vinorelbine to Novacea, while Pierre Fabre will continue to develop and commercialize oral vinorelbine in Europe and
These data are important to physicians and patients because resistance to treatment is one of the major challenges in trying to control HIV/AIDS. The virus can become resistant